Literature DB >> 10823751

Cytotoxic T lymphocyte (CTL) responses to human cytomegalovirus pp65, IE1-Exon4, gB, pp150, and pp28 in healthy individuals: reevaluation of prevalence of IE1-specific CTLs.

Z Gyulai1, V Endresz, K Burian, S Pincus, J Toldy, W I Cox, C Meric, S Plotkin, E Gönczöl, K Berencsi.   

Abstract

The prevalence of human cytomegalovirus (HCMV) pp65-, pp150-, IE1-exon4-, gB- and pp28-specific cytotoxic T lymphocyte (CTL) responses was compared among 34 healthy individuals, grouped by neutralizing antibody titers. Moderately and highly seropositive donors showed predominantly pp65- and IE1-exon4-specific CTL responses (92% and 76% of the donors, respectively), with similar precursor frequencies in the 2 donors tested. In addition, highly seropositive and a few moderately seropositive donors showed CTL responses to gB and pp150 (33% and 30% of the donors, respectively). No individual recognized pp28 as a target in the CTL assay. Phenotypic analysis revealed a mixed effector population of CD4+ and CD8+ (1 donor) or only CD8+ cells for pp65-specific effectors (2 donors). IE1-exon4- and pp150-specific effectors were CD8+ (2 donors and 1 donor, respectively), whereas gB-specific CTLs were CD4+ (1 donor). These data may help to design a cellular immunity-based vaccine effective against HCMV diseases.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10823751     DOI: 10.1086/315445

Source DB:  PubMed          Journal:  J Infect Dis        ISSN: 0022-1899            Impact factor:   5.226


  31 in total

1.  Infrequent occurrence of natural mutations in the pp65(495-503) epitope sequence presented by the HLA A*0201 allele among human cytomegalovirus isolates.

Authors:  J A Zaia; G Gallez-Hawkins; X Li; Z Q Yao; N Lomeli; K Molinder; C La Rosa; D J Diamond
Journal:  J Virol       Date:  2001-03       Impact factor: 5.103

2.  Cross-reactivity of HLA-B*1801-restricted T-lymphocyte clones with target cells expressing variants of the human cytomegalovirus 72kDa-IE1 protein.

Authors:  Virginie Prod'homme; Christelle Retière; Ralitza Valtcheva; Marc Bonneville; Marie-Martine Hallet
Journal:  J Virol       Date:  2003-06       Impact factor: 5.103

3.  Use of transgenic HLA A*0201/Kb and HHD II mice to evaluate frequency of cytomegalovirus IE1-derived peptide usage in eliciting human CD8 cytokine response.

Authors:  Ghislaine Gallez-Hawkins; Maria C Villacres; Xiuli Li; Margaret C Sanborn; Norma A Lomeli; John A Zaia
Journal:  J Virol       Date:  2003-04       Impact factor: 5.103

Review 4.  Contributions of humoral and cellular immunity to vaccine-induced protection in humans.

Authors:  Ian J Amanna; Mark K Slifka
Journal:  Virology       Date:  2011-01-08       Impact factor: 3.616

5.  Vaccine properties of a novel marker gene-free recombinant modified vaccinia Ankara expressing immunodominant CMV antigens pp65 and IE1.

Authors:  Zhongde Wang; Corinna La Rosa; Zhongqi Li; Heang Ly; Aparna Krishnan; Joy Martinez; William J Britt; Don J Diamond
Journal:  Vaccine       Date:  2006-10-06       Impact factor: 3.641

Review 6.  Herpesvirus interference with major histocompatibility complex class II-restricted T-cell activation.

Authors:  Emmanuel J Wiertz; Robert Devlin; Helen L Collins; Maaike E Ressing
Journal:  J Virol       Date:  2006-11-01       Impact factor: 5.103

7.  Cellular and humoral immune responses to alphavirus replicon vaccines expressing cytomegalovirus pp65, IE1, and gB proteins.

Authors:  Elizabeth A Reap; Sergey A Dryga; John Morris; Bryan Rivers; Pamela K Norberg; Robert A Olmsted; Jeffrey D Chulay
Journal:  Clin Vaccine Immunol       Date:  2007-04-18

8.  Human cytomegalovirus pp65 lower matrix protein: a humoral immunogen for systemic lupus erythematosus patients and autoantibody accelerator for NZB/W F1 mice.

Authors:  M Chang; M-R Pan; D-Y Chen; J-L Lan
Journal:  Clin Exp Immunol       Date:  2006-01       Impact factor: 4.330

9.  Rapid Acquisition of Cytomegalovirus-Specific T Cells with a Differentiated Phenotype, in Nonviremic Hematopoietic Stem Transplant Recipients Vaccinated with CMVPepVax.

Authors:  Corinna La Rosa; Jeffrey Longmate; Chetan Raj Lingaraju; Qiao Zhou; Teodora Kaltcheva; Nicola Hardwick; Ibrahim Aldoss; Ryotaro Nakamura; Don J Diamond
Journal:  Biol Blood Marrow Transplant       Date:  2018-12-16       Impact factor: 5.742

10.  Molecular, biological, and in vivo characterization of the guinea pig cytomegalovirus (CMV) homologs of the human CMV matrix proteins pp71 (UL82) and pp65 (UL83).

Authors:  Alistair McGregor; Fenyong Liu; Mark R Schleiss
Journal:  J Virol       Date:  2004-09       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.